PMID- 24804240
OWN - NLM
STAT- MEDLINE
DCOM- 20150105
LR  - 20220317
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2014
DP  - 2014
TI  - mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment.
PG  - 735672
LID - 10.1155/2014/735672 [doi]
LID - 735672
AB  - As the fifth most common cancer in men and the eighth most common cancer in 
      women, hepatocellular carcinoma (HCC) is the leading cause of cancer-related 
      deaths worldwide, with standard chemotherapy and radiation being minimally 
      effective in prolonging survival. Virus hepatitis, particularly HBV and HCV 
      infection is the most prominent risk factor for HCC development. Mammalian target 
      of rapamycin (mTOR) pathway is activated in viral hepatitis and HCC. mTOR 
      inhibitors have been tested successfully in clinical trials for their 
      antineoplastic potency and well tolerability. Treatment with mTOR inhibitor alone 
      or in combination with cytotoxic drugs or targeted therapy drug scan 
      significantly reduces HCC growth and improves clinical outcome, indicating that 
      mTOR inhibition is a promising strategy for the clinical management of HCC.
FAU - Wang, Zhuo
AU  - Wang Z
AD  - Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw 
      Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
FAU - Jin, Wei
AU  - Jin W
AD  - Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw 
      Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
FAU - Jin, Hongchuan
AU  - Jin H
AD  - Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw 
      Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
FAU - Wang, Xian
AU  - Wang X
AD  - Department of Medical Oncology, Institute of Clinical Science, Sir Runrun Shaw 
      Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140402
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Carcinoma, Hepatocellular/*drug therapy/genetics/pathology
MH  - Female
MH  - Hepatitis/drug therapy/genetics/virology
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/genetics/pathology
MH  - Male
MH  - Protein Kinase Inhibitors/*administration & dosage
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*genetics
PMC - PMC3996896
EDAT- 2014/05/08 06:00
MHDA- 2015/01/06 06:00
PMCR- 2014/04/02
CRDT- 2014/05/08 06:00
PHST- 2013/11/08 00:00 [received]
PHST- 2014/03/07 00:00 [accepted]
PHST- 2014/05/08 06:00 [entrez]
PHST- 2014/05/08 06:00 [pubmed]
PHST- 2015/01/06 06:00 [medline]
PHST- 2014/04/02 00:00 [pmc-release]
AID - 10.1155/2014/735672 [doi]
PST - ppublish
SO  - Biomed Res Int. 2014;2014:735672. doi: 10.1155/2014/735672. Epub 2014 Apr 2.